What question did this study set out to answer?

This research aims to identify clinicopathological findings and prognostic factors in patients with primary central nervous system lymphoma.

March 4, 2026Open Access

Prognostic Factors Influencing Treatment Response in Primary Central Nervous System Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Examines treatment effects and prognostic factors in patients with primary CNS lymphoma, suggesting implications for management.

This research aims to identify clinicopathological findings and prognostic factors in patients with primary central nervous system lymphoma.
Retrospective analysis of 84 patients diagnosed with PCNSL from January 2008 to July 2021.
Examination of treatment approaches and survival outcomes.
Evaluation of consolidation therapy's impact on overall and progression-free survival.
Median age at diagnosis was 55 years, with a median progression-free survival of 16.8 months.
Overall survival was 18 months, with high-dose methotrexate as the most common treatment.
Consolidation therapy improved mortality outcomes, showing a 67% reduction in death risk for treated patients.

Mehmet Faruk Yıldırım (2025) studied this question.

View Full Paper

Ask AI

Bookmark